Description

• Feline broad-spectrum antibiotic in two oral dosage forms: oral solution and tablets.



• Combines broad-spectrum antibiotic activity of amoxicillin with unique β-lactamase inhibiting effect of clavulanic acid, which extends the antibacterial spectrum to β-lactamase-producing and non-β-lactamase-producing organisms.



• Has activity against many gram-positive and gram-negative aerobic and anaerobic microorganisms.

• Skin and soft-tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: β-lactamase-producing Staphylococcus aureus, non-β-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, Pasteurella multocida and Pasteurella spp.



• Urinary tract infections (cystitis) due to susceptible strains of E. coli

• Overcomes β-lactamase resistance by irreversibly binding β-lactamase to clavulanic acid component, allowing amoxicillin component to exert antibacterial effect.



• Unique, dual mode of action minimizes resistance to CLAVAMOX despite extensive real-world clinical use.



• Effective for first-time skin infections and persistent pyodermas.



• Effective in treating mixed periodontal infections involving aerobic and anaerobic bacteria.



• Wide margin of safety, with no contraindications other than allergic history.



• Offers duration of therapy of up to 30 days.

• Use is contraindicated in animals with a history of an allergic reaction to any of the penicillins or cephalosporins.



• CLAVAMOX contains a semi-synthetic penicillin (amoxicillin) and has the potential for producing allergic reactions. If an allergic reaction occurs, administer epinephrine and/or steroids.



• Safety in pregnant or breeding animals has not been determined.



• Store in a dry, cool place at temperatures not above 25° C (77° F).



• Do not remove CLAVAMOX TABLETS from foil strip until ready to use.



• Federal law restricts use by or on the order of a licensed veterinarian.